How actively should we screen for chlamydia and gonorrhoea in MSM and other high-ST-prevalence populations as we enter the era of increasingly untreatable infections? A viewpoint

References

1. European Centre for Disease Prevention and Control Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia Stockholm: ECDC; 2018
   [Google Scholar]
2. O’Neill J. Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations London: Review on Antimicrobial Resistance; 2014
   [Google Scholar]
3. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 2014;14:13 [CrossRef][PubMed]
   [Google Scholar]
4. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579–587 [CrossRef][PubMed]
   [Google Scholar]
5. Klein EY, van Boeckel TP, Martinez EM, Pant S, Gandra S et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA 2018;115:E3463E3470 [CrossRef][PubMed]
   [Google Scholar]
6. Kenyon C, Buyze J, Wi T. Antimicrobial consumption and susceptibility of Neisseria gonorrhoeae: a global ecological analysis. Frontiers in Medicine
   [Google Scholar]
7. Kenyon C. Prevalence of macrolide resistance in Treponema pallidum is associated with macrolide consumption. J Med Microbio (In Submission)
   [Google Scholar]
8. Kenyon CR, de Baetselier I, Crucitti T. Does gonorrhoea screening intensity play a role in the early selection of antimicrobial resistance in men who have sex with men (MSM)? A comparative study of Belgium and the United Kingdom. F1000Res 2018;7:569 [CrossRef][PubMed]
   [Google Scholar]
9. Kenyon CR. Association between intensity of STI screening and development of antimicrobial resistance in N. gonorrhoeae in 12 cities in the USA: An ecological study. F1000Res 2018;7:1237 [CrossRef][PubMed]
   [Google Scholar]
10. Belgian Research AIDS & HIV Consortium Use of Pre Exposure Prophylaxis (PrEP). Belgian guidelines 2017
    [Google Scholar]
11. Tan DHS, Hull MW, Yoong D, Tremblay C, O'Byrne P et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017;189:E1448E58 [CrossRef][PubMed]
    [Google Scholar]
12. World Health Organization Global health sector strategy on sexually transmitted infections 2016–2021. Towards ending STIs Geneva: WHO; 2016; WHO/RHR/16.09
    [Google Scholar]
13. García PJ, Holmes KK, Cárcamo CP, Garnett GP, Hughes JP et al. Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet 2012;379:1120–1128 [CrossRef][PubMed]
    [Google Scholar]
14. Low N, Redmond S, Uusküla A, van Bergen J, Ward H et al. Screening for genital chlamydia infection. Cochrane Db Syst Rev 2016;9:CD010866 [CrossRef][PubMed]
    [Google Scholar]
15. Zakher B, Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for gonorrhea and Chlamydia: a systematic review for the U.S. preventive services task force. Ann Intern Med 2014;161:884–U81 [CrossRef][PubMed]
    [Google Scholar]
16. van den Broek IV, van Bergen JE, Brouwers EE, Fennema JS, Götz HM et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ 2012;345:e4316 [CrossRef][PubMed]
    [Google Scholar]
17. Hocking JS, Temple-Smith M, Guy R, Donovan B, Braat S et al. Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. Lancet 2018;392:1413–1422 [CrossRef][PubMed]
    [Google Scholar]
18. Tsoumanis A, Hens N, Kenyon CR. Is screening for chlamydia and gonorrhea in men who have sex with men associated with reduction of the prevalence of these infections? a systematic review of observational studies. Sex Transm Dis 2018;45:1 [CrossRef][PubMed]
    [Google Scholar]
19. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587–2599 [CrossRef][PubMed]
    [Google Scholar]
20. Buyze J, vanden Berghe W, Hens N, Kenyon C. Current levels of gonorrhoea screening in MSM in Belgium may have little effect on prevalence: a modelling study. Epidemiol Infect 2018;146:333–338 [CrossRef][PubMed]
    [Google Scholar]
21. Kenyon C. We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in PrEP cohorts. AIDS 2018;1 [CrossRef][PubMed]
    [Google Scholar]
22. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N gonorrhoeae. Sex Transm Infect 2013;89:iv47–iv51 [CrossRef][PubMed]
    [Google Scholar]
23. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med 2017;14:e1002344 [CrossRef][PubMed]
    [Google Scholar]
24. Kenyon CR, Osbak K, Tsoumanis A. The Global Epidemiology of Syphilis in the Past Century - A Systematic Review Based on Antenatal Syphilis Prevalence. PLoS Negl Trop Dis 2016;10:e0004711 [CrossRef][PubMed]
    [Google Scholar]
25. Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013;382:1795–1806 [CrossRef][PubMed]
    [Google Scholar]
26. Wilson JMG, Jungner G. Principles and practice of screening for disease Geneva: World Health Organization; 1968
    [Google Scholar]